Step-down steroid-sparing therapy in active thyroid eye disease

Mario Salvi

Research output: Contribution to journalArticlepeer-review


Intravenous steroid therapy in thyroid eye disease has limitations and is potentially harmful at high doses. A steroid-sparing approach is a reasonable option, but combination therapy must be tested in randomized clinical trials designed to establish the efficacy and the potentially increased risk of adverse effects of combined immunosuppressive treatment.

Original languageEnglish
Pages (from-to)634-635
JournalNature Reviews Endocrinology
Issue number11
Publication statusPublished - 2018

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Step-down steroid-sparing therapy in active thyroid eye disease'. Together they form a unique fingerprint.

Cite this